These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1441044)

  • 41. Norfloxacin use in urinary tract infection by urologists and infectious disease specialists.
    Kunkel MJ; Iannini PB; Landes R; Harrison L; Wells G; Snow R; Schaeffer AJ; Goldstein EJ; Berman S
    Eur Urol; 1990; 17 Suppl 1():30-3. PubMed ID: 2354709
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical evaluation of norfloxacin preparation in treatment of bacterial infections of the urinary tract in patients with various kidney diseases].
    Mazanowska O; Boratyńska M; Mróz E; Starek J
    Pol Tyg Lek; 1994 Feb 7-14; 49(6-7):154-7. PubMed ID: 8090671
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ciprofloxacin: an update on clinical experience.
    Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Becker N; August R
    Am J Med; 1987 Apr; 82(4A):381-6. PubMed ID: 3555063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical study of the effectiveness and tolerance of norfloxacin in the therapy of complicated urinary tract infections and in long-term prevention of recurrent urinary tract infections].
    Westenfelder M; Pelz K; Frankenschmidt A; Vahlensieck W
    Infection; 1987; 15(1):20-4. PubMed ID: 3106227
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral norfloxacin versus parenteral treatment of nosocomial urinary tract infection.
    Cox CE; McCabe RE; Grad C
    Am J Med; 1987 Jun; 82(6B):59-64. PubMed ID: 3300312
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of norfloxacin 800 mg once-daily versus norfloxacin 400 mg twice-daily in the treatment of uncomplicated urinary tract infections in women: a double-blind, randomized clinical trial.
    Pimentel FL; Dolgner A; Guimarães J; Quintas M; Mário-Reis J
    J Chemother; 1998 Apr; 10(2):122-7. PubMed ID: 9603637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Norfloxacine efficacy in acute cystitis in the region with 10% resistance of E. coli to fluoroquinolones: a comparative randomized study].
    Rafal'skiĭ VV; Malev IV; Derevitskiĭ AV; Kozlov SN; Galkin VV
    Urologiia; 2009; (3):18-21. PubMed ID: 19670810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group.
    McCarty JM; Richard G; Huck W; Tucker RM; Tosiello RL; Shan M; Heyd A; Echols RM
    Am J Med; 1999 Mar; 106(3):292-9. PubMed ID: 10190377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiclinic study of norfloxacin for treatment of urinary tract infections.
    Schaeffer AJ
    Am J Med; 1987 Jun; 82(6B):53-8. PubMed ID: 3300311
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Double-blind comparison of 3-day versus 7-day treatment with norfloxacin in symptomatic urinary tract infections. The Inter-Nordic Urinary Tract Infection Study Group.
    Scand J Infect Dis; 1988; 20(6):619-24. PubMed ID: 2906171
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The efficacy and safety of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection.
    Brown EM; Morris R; Stephenson TP
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():123-7. PubMed ID: 3804900
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complicated urinary tract infections treated with extended-release ciprofloxacin with emphasis on Pseudomonas aeruginosa.
    Saltzstein D; Wachs B; Perroncel R; Benson A; Herrington J; Haverstock D; Pertel P
    J Chemother; 2007 Dec; 19(6):694-702. PubMed ID: 18230553
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Complicated urinary infection in spinal injury patients: fleroxacin compared with ciprofloxacin.
    Whitby M; Angus L; Nimmo G; Hill V
    Chemotherapy; 1996; 42(6):468-72. PubMed ID: 8957583
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effective postcoital quinolone prophylaxis of recurrent urinary tract infections in women.
    Pfau A; Sacks TG
    J Urol; 1994 Jul; 152(1):136-8. PubMed ID: 8201643
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. The South Swedish Lolex Study Group.
    Neringer R; Forsgren A; Hansson C; Ode B
    Scand J Infect Dis; 1992; 24(6):773-80. PubMed ID: 1337623
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cefodizime (HR221) versus norfloxacin for treatment of urinary tract infections.
    Esposito S; Sardaro C; Gaeta GB; Galante D; Giusti G; Basani F
    J Chemother; 1991 Feb; 3(1):42-4. PubMed ID: 2019862
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical study of NFLX (norfloxacin) in complicated urinary tract infections].
    Murase T; Mitsuya H; Fukatsu H; Yoshida K; Natsume H; Obata K; Ohshima S; Asaka H; Kobayashi M; Okamura K
    Hinyokika Kiyo; 1986 Aug; 32(8):1167-75. PubMed ID: 3788743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Time to symptom relief for uncomplicated urinary tract infection treated with extended-release ciprofloxacin: a prospective, open-label, uncontrolled primary care study.
    Klimberg I; Shockey G; Ellison H; Fuller-Jonap F; Colgan R; Song J; Keating K; Cyrus P
    Curr Med Res Opin; 2005 Aug; 21(8):1241-50. PubMed ID: 16083534
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lomefloxacin versus norfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections.
    Naber KG
    Int J Antimicrob Agents; 1992 Dec; 2(1):33-7. PubMed ID: 18611517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.